Patents Examined by Jennifer C Sawyer
  • Patent number: 11401235
    Abstract: The present invention relates novel methods of synthesizing terphenyl compounds and in particular to novel methods for the synthesis of a compound of Formula I or intermediates thereof.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: August 2, 2022
    Inventors: Anthony Kaye, Nurul Quazi, George Feast, Marshnil Lakshman
  • Patent number: 11398645
    Abstract: Processes and reaction mixtures including non-aqueous solvent mixtures are presented. Non-aqueous solvent mixtures including fluoride salt and non-aqueous solvent combinations are provided that possess high fluoride ion concentrations useful for a range of applications, including organic synthesis. Further non-aqueous solvent mixtures are provided including a salt possessing a non-fluoride anion and a non-aqueous solvent that, when contacted with aqueous fluoride-containing reagents, extract fluoride ions to form non-aqueous fluoride-ion solutions possessing high fluoride-ion concentrations. The salts include an organic cation that does not possess a carbon in the ?-position or does not possess a carbon in the ?-position having a bound hydrogen. This salt structure facilitates its ability to be made anhydrous without decomposition. Example anhydrous fluoride salts include (2,2-dimethylpropyl)trimethylammonium fluoride and bis(2,2-dimethylpropyl)dimethylammonium fluoride.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 26, 2022
    Assignees: California Institute of Technology, The Regents of the University of California
    Inventors: Simon C. Jones, Victoria K. Davis, Christopher M. Bates, Nebojsa Momcilovic, Brett M. Savoie, Michael A. Webb, Thomas F. Miller, III, Robert H. Grubbs, Jennifer M. Murphy
  • Patent number: 11390579
    Abstract: The invention concerns a new, efficient process for the preparation of enantiomerically pure norepinephrine (also known as noradrenaline), or an addition salt thereof, using a catalytic hydrogenation system under hydrogen donor transfer. The invention also discloses a novel intermediate and the process for the preparation thereof.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: July 19, 2022
    Assignee: Edmond Pharma, s.r.l.
    Inventors: Matteo Zacche', Pier Andrea Gatti, Fulvio Gerli, Davide Sbarbada, Fabio Rondina
  • Patent number: 11377416
    Abstract: The present invention provides novel, stable, processable and pharmaceutically acceptable salt forms of 2R,6R-hydroxynorketamine or 2S,6S-hydroxynorketamine with high aqueous solubility.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: July 5, 2022
    Assignee: SMALL PHARMA LTD.
    Inventors: David Pearson, Lorraine Sharp, Alan Armstrong, Richard Myerson, Jonathan Hull, Paul Blaney, Peter Rands, Marie Layzell, Zelah Joel
  • Patent number: 11369586
    Abstract: Described herein are antifungal peptoids, the development and characterization of the antifungal peptoids, methods of making the antifungal peptoids, and methods of using the antifungal peptoids. In some embodiments, the antifungal peptoids may be administered to a subject infected with or at risk of being infected with pathogenic fungi including, for example Cryptococcus spp. In some embodiments, the Cryptococcus spp. may include C. neoformans or C. gattii or both.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: June 28, 2022
    Assignee: Middle Tennessee State University
    Inventors: Kevin L. Bicker, Madyson P. Middleton, Scott A. Armstrong
  • Patent number: 11370740
    Abstract: The present invention provides a novel method for producing an ester group-containing compound and a derivative produced using the compound as a synthetic intermediate. The invention also provides a polymerizable composition containing the compound obtained by the production method and a film-shaped polymer obtained by polymerizing the polymerizable composition. The present invention is a method for producing an ester group-containing compound, the method including a mixing step of mixing a condensing agent, a Bronsted acid, a carboxylic acid, and a phenol or an alcohol to prepare a reaction mixture. The Bronsted acid selected is other than the condensing agent, the carboxylic acid, and the phenol.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: June 28, 2022
    Inventors: Masahiro Horiguchi, Toru Tsuruta
  • Patent number: 11370666
    Abstract: A method of preparing pentachlorodisilane is disclosed. The method comprises partially reducing hexachlorodisilane with a metal hydride compound to give a reaction product comprising pentachlorodisilane. The method further comprises purifying the reaction product to give a purified reaction product comprising the pentachlorodisilane. The purified reaction product comprising pentachlorodisilane formed in accordance with the method is also disclosed.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 28, 2022
    Assignee: Jiangsu Nata Opto-Electronic Materials Co. Ltd.
    Inventors: Barry Ketola, Noel Mower Chang, Jeanette Young, Xiaobing Zhou
  • Patent number: 11345657
    Abstract: Here are described processes for the preparation of sulfamic acid derivatives, for instance, halogenated derivatives and their metallic or organic salts. The present document also describes the sulfamic acid derivatives thus produced and to their uses, for instance, in electrolyte compositions for electrochemical applications.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: May 31, 2022
    Assignee: HYDRO-QUEBEC
    Inventors: Matjaz Kozelj, Catherine Gagnon, Abdelbast Guerfi, Karim Zaghib
  • Patent number: 11345706
    Abstract: The present invention provides crystalline forms of Acalabrutinib, Specific crystalline forms provided by the present invention include Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: May 31, 2022
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya, Wancheng Guo, Jingda Zhang, Kun Cheng, Kangying Li
  • Patent number: 11339116
    Abstract: A process to convert cyclic alkylene ureas into their corresponding alkylene amines is provided. An exemplary process includes reacting the cyclic alkylene ureas with an amine compound chosen from the group of primary amines or secondary amines that have a higher boiling point than the alkylene amines formed during the process, wherein the process is a reactive separation process and the reaction mixture contains less than about 10 wt % of water on the basis of total weight of the reaction mixture.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: May 24, 2022
    Inventors: Rens Veneman, Antoon Jacob Berend Ten Kate, Karl Fredrik Lake, Eike Nicolas Kantzer, Slavisa Jovic, Rolf Krister Edvinsson, Ina Ehlers, Hendrik Van Dam, Michiel Jozef Thomas Raaijmakers
  • Patent number: 11332435
    Abstract: The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: May 17, 2022
    Inventors: Peter Fey, Philipp Rubenbauer, Kai Lovis, Britta Olenik, Julia Kusel, Felix Spindler
  • Patent number: 11325875
    Abstract: Chiral spirobiindane skeleton compound and preparation method thereof is disclosed in the present invention. The spirobiindane skeleton compound of the present invention having the structure formula of I or I?; the preparation method for synthesizing the spirobiindane skeleton compound of the present invention comprising the following steps: in the presence of solvent and catalysts, the structure formula compound III reacted through intramolecular Friedel-Crafts reaction to obtain the compound of formula I; the catalyst is a Browsteric acidor Lewis acid. The preparation method of chiral fused spirobiindane skeleton compound of the present invention does not need to adopt chiral starting materials or chiral resolving agents, does not require chiral resolving steps, is simple in method, is simple in post-treatment, and is economic and environment friendly. High product yield, high product optical purity and chemical purity.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: May 10, 2022
    Inventors: Kuiling Ding, Yuxi Cao, Zhiyao Zheng, Qinglei Chong, Zheng Wang
  • Patent number: 11325886
    Abstract: Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: May 10, 2022
    Assignee: Oregon Health & Science University
    Inventors: Thomas S. Scanlan, James Matthew Meinig, Skylar J. Ferrara, Tapasree Banerji, Tania Banerji
  • Patent number: 11328832
    Abstract: A catalyst-free synthesis method for the formation of a metalorganic compound comprising a desired (first) metal may include, for example, selecting another (second) metal and an organic solvent, with the second metal being selected to (i) be more reactive with respect to the organic solvent than the first metal and (ii) form, upon exposure of the second metal to the organic solvent, a reaction by-product that is more soluble in the organic solvent than the metalorganic compound. An alloy comprising the first metal and the second metal may be first produced (e.g., formed or otherwise obtained) and then treated with the organic solvent in a liquid phase or a vapor phase to form a mixture comprising (i) the reaction by-product comprising the second metal and (ii) the metalorganic compound comprising the first metal. The metalorganic compound may then be separated from the mixture in the form of a solid.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: May 10, 2022
    Inventors: Gleb Yushin, James Benson, Danni Lei, Eugene Berdichevsky
  • Patent number: 11319282
    Abstract: The present invention provides a novel diamine compound capable of producing a polymer which exhibits greatly enhanced mechanical properties and heat resistance while maintaining transparency. A film including a polymer produced using the diamine compound has excellent transparency, heat resistance, mechanical strength and flexibility, and thus can be used in various fields, such as in a device substrate, a display cover substrate, an optical film, an Integrated circuit (IC) package, an adhesive film, a multi-layer flexible printed circuit (FPC), a tape, a touch panel and an optical disc protection film, and the like.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: May 3, 2022
    Assignee: LG CHEM, LTD.
    Inventors: Cheolmin Yun, Jun Sik Suh, Kyungjun Kim
  • Patent number: 11319274
    Abstract: The invention relates to a robust and reproducible process for the preparation of polymorph form B of treprostinil diethanolamine salt, comprising the following steps: a. treprostinil is dissolved in methanol, b. to the solution of step a) diethanolamine or its methanol solution is added, c. the reaction mixture of step b) is agitated till dissolution, d. when salt formation is completed in step c), first portion of an aprotic solvent is added to the solution, e. the solution of step d) is filtered to remove insoluble impurities, f. the filtrate of step e) is seeded with polymorph form B of treprostinil diethanolamine salt, g. to the crystal suspension obtained in step f) a second portion of the aprotic solvent is added, h. the suspension of step g) is agitated until crystallisation is completed, i. the crystals are separated, washed and dried.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: May 3, 2022
    Inventors: Irén Hortobágyi, István Lászlófi, Zoltán Varga, Imre Juhász, Imola Ritz, Zsuzsanna Kardos
  • Patent number: 11299448
    Abstract: An active ester compound that can form a cured product having excellent dielectric properties and copper foil adhesion properties is provided, a curable composition including the active ester compound is provided, and a cured product of the curable composition is provided. Also provided are a semiconductor encapsulating material, a printed wiring board, and a build-up film formed by using the curable composition. Specifically, an active ester compound is provided which includes a fluorinated hydrocarbon structural moiety and a plurality of aromatic ester structural moieties in the structure of the molecule and includes an aryloxycarbonyl structure or an arylcarbonyloxy structure at an end of the molecule, a curable composition including the active ester compound, and a cured product of the curable composition, and also provided are a semiconductor encapsulation material, a printed wiring board, and a build-up film formed by using the curable composition.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: April 12, 2022
    Assignee: DIC Corporation
    Inventors: Tatsuya Okamoto, Yutaka Satou
  • Patent number: 11299451
    Abstract: A method for synthesizing 2-(1-cyclohexenyl)ethylamine. Cyclohexanone (II) is reacted with a Grignard reagent in a first organic solvent to produce 1-vinylcyclohexanol (III), which is then subjected to chlorination and rearrangement reaction with a chlorinating reagent in a second organic solvent in the presence of an organic base to synthesize (2-chloroethylmethylene)cyclolxane (IV). Then (2-chloroethylmethylene)cyclohexane (IV) and urotropine are subjected to quaternization in a third organic solvent to synthesize N-cyclohexylidene ethyl urotropine hydrochloride (V). Finally, the N-cyclohexylidene ethyl urotropine hydrochloride (V) undergoes hydrolysis and rearrangement reaction in a solvent in the presence of an inorganic mineral acid to synthesize 2-(1-cyclohexenyl)ethylamine (I).
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: April 12, 2022
    Assignee: Fudan University
    Inventors: Fener Chen, Dang Cheng, Zedu Huang, Zhining Li, Meifen Jiang, Yuan Tao
  • Patent number: 11286230
    Abstract: The invention provides a method for synthesizing a compound of formula wherein each R independently represents an optionally substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy, acyl, carboxyl, hydroxyl, halogen, amino, nitro, cyano, sulfo or sulfhydryl group, in ortho, meta or para position to the cycloalkylamine moiety; R1 and R2 each independently represents a hydrogen atom, a lower alkyl group or a cycloalkyl group; R3 represents a hydrogen group, substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy group; Y represents an oxygen atom, a sulfur atom, a NH group, a NR4 group or a CH2 group; R4 represents a hydrogen atom or an alkyl, aryl or a heteroaryl group; and n and m each independently represents an integer from 1 to 5; or a pharmaceutically acceptable salt thereof; or a precursor thereof; wherein the method comprises one or more of the following steps: (a) reacting a compound of formula (II) wherein R, R3, Y, n and m are as defined ab
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: March 29, 2022
    Inventors: Thomas Toupy, Romaric Gerardy, Jean-Christophe Monbaliu, Diego Collin, Victor-Emmanuel Kassin
  • Patent number: 11286236
    Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: March 29, 2022
    Inventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin